Latest / Durham News Today | 2 Min News | The Daily News Now!
Lilly’s Bull Case Under Fire | Durham News
Wall Street’s bullish on Eli Lilly, with banks like UBS, JPMorgan, and Bank of America raising targets to as high as $1,425, fueled by blockbuster sales of Mounjaro and Zepbound—and hopes for Alzheimer’s drug Kisunla. But investor enthusiasm is tempered by flat early sales of new diabetes pill Foundayo, raising questions about its market adoption. With earnings due August 5th, investors will scrutinize Foundayo’s performance, international Mounjaro momentum, and whether demand can withstand falling prices—making this a pivotal moment for the stock. Listen in comfort:Get a discount on a Soli…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.